Flow cytometric analysis of Human CD83 expression on PHA-treated Human PBMC. Human PBMC (peripheral blood mononuclear cells) treated 48h with 10μg/ml PHA (Right panel) or untreated (Left panel) were stained with SDT PE Mouse Anti-Human CD83 Antibody at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD83 |
| Synonyms | CD83 antigen; hCD83; B-cell activation protein; Cell surface protein HB15 |
| Location | Membrane |
| Accession | Q01151 |
| Clone Number | S-3040 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | PHA-treated Human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | PE |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD83 is a ~45 kDa, heavily glycosylated type-I transmembrane glycoprotein of the immunoglobulin superfamily that is encoded on human chromosome 6 and expressed chiefly on mature dendritic cells, Langerhans cells and activated lymphocytes, where it serves as a key maturation marker whose extracellular V-set Ig-like domain can dimerize via a membrane-proximal cysteine and whose membrane-bound form drives potent T-cell stimulation while its proteolytically released soluble counterpart (sCD83) exerts potent immunosuppressive effects by inhibiting dendritic-cell maturation and cytokine production, thereby modulating both the initiation and resolution of adaptive immune responses.
Picture
Picture
FC
